SAMSUNG BIOLOGICS Co., Ltd.

TEL AVIV, Israel & LOS ANGELES--( BUSINESS WIRE )-- Classiq , a leading quantum computing software company, and Florence Quantum Labs today announced their collaboration on research to develop quantum-enhanced precision agriculture. This announcement comes as 2025 kicks off the International Year of Quantum Science and Technologies, underscoring the global significance of quantum advancements in addressing critical challenges. This collaborative research will use the Classiq platform to develop quantum computing solutions in precision agriculture for a wide range of predictive and analytical applications. It will leverage Florence Quantum Lab-designed quantum-enhanced biosensors and include deployment of scalable AI-quantum hybrid algorithms for ecosystem modeling. The partnership focuses on significantly enhancing the efficiency and accuracy of soil health monitoring and nutrient management by integrating Classiq's quantum computing platform with Florence Quantum Labs' advanced agricultural technologies. Classiq offers a leading quantum development platform with unique technology enabling high-level abstraction that simplifies and accelerates development of efficient complex quantum programs and applications. The Classiq platform’s built-in functions, GitHub repository and seamless execution on a broad range of quantum computing hardware will be key components in the research to develop transformative agricultural solutions. “Our work together on the application of quantum computing to precision agriculture is an inspiring use case,” said Classiq CEO Nir Minerbi . “Classiq looks forward to enabling the development of sophisticated, optimized quantum programs to help tackle food security challenges.” “This partnership represents a pivotal step toward harnessing quantum computing to address global food security challenges,” said Florence Quantum Labs CEO Dr. Pratima Vasistha . “By combining Classiq’s innovative platform with our expertise in precision agriculture, we are set to revolutionize sustainable farming practices.” Florence Quantum Labs is pioneering the integration of quantum technologies to address critical challenges in sustainable farming and global food security. Through a rigorous multidisciplinary approach, the laboratory has established itself as a leader in the development of advanced quantum-enhanced biosensors, which provide unparalleled accuracy in real-time soil health diagnostics. These biosensors are coupled with AI-quantum hybrid algorithms, designed to optimize nutrient delivery systems and reduce inefficiencies in agricultural processes. The lab’s work extends to the creation of comprehensive ecosystem models that leverage quantum computational capabilities to analyze complex soil microbiome interactions and nutrient pathways. By tailoring these solutions to diverse agro-climatic zones, Florence Quantum Labs ensures that their innovations are scalable and adaptable to global agricultural needs. Their research agenda also includes advancing bioinformatics methodologies through quantum-based algorithms, enabling deeper insights into soil ecosystems and driving the development of precision agri-bio solutions. In alignment with climate-smart agricultural practices, Florence Quantum Labs’ commitment to sustainable innovation addresses the twin goals of mitigating climate change impacts and enhancing the resilience of agricultural systems. Their work contributes to reducing environmental footprints while ensuring the productivity required to meet the demands of a growing global population. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn , X or YouTube , visit the Slack community , GitHub repository and website, www.classiq.io to learn more. About Florence Quantum Lab Florence Quantum Labs is a leading innovator in the emerging field of quantum-enhanced precision agriculture, harnessing the transformative potential of quantum technologies to address critical challenges in sustainable farming and global food security. The laboratory’s multidisciplinary approach integrates advanced quantum-enhanced biosensors, sophisticated AI-quantum hybrid algorithms, and comprehensive ecosystem modeling to drive unprecedented accuracy in agricultural processes. By enabling real-time soil health diagnostics, optimizing nutrient pathways, and delivering predictive analytics tailored to diverse agro-climatic zones, Florence Quantum Labs is paving the way for a new era of climate-smart agriculture. Their commitment to advancing soil microbiome research and developing scalable, data-driven solutions positions them at the forefront of efforts to mitigate the impacts of climate change, enhance ecological resilience, and ensure the productivity necessary to meet global food demands in a sustainable manner.

Following a blockbuster 2024, Samsung Biologics is considering building a sixth manufacturing facility to meet the rising demand for biologics as it gears up to open its fifth site in April. During the annual JP Morgan Healthcare Conference in San Francisco this week, Samsung Bio hinted that it might construct its sixth factory to bring its total capacity to 964,000 liters, according to a Tuesday press release . The CDMO is awaiting board approval for the new site. Last year, the company seemed to buck the trend of CDMOs struggling: Merck KGaA , Catalent, Avid Bioservices and Thermo Fisher Scientific all saw manufacturing revenue dip during at least one quarter in 2024. Samsung Bio, by contrast, secured multiple billion-dollar contracts with customers and reported quarterly revenue jumps. Samsung intends to build on this growth by opening its fifth manufacturing facility, dubbed Plant 5, in April this year. Plant 5 will be the first building on its Bio Campus II plot in Songdo, South Korea — about a half-hour drive southwest of Seoul — and will increase the company’s total capacity to 784,000 liters. Construction of Plant 5 was announced in March 2023. Further, the CDMO said that its antibody-drug conjugates services are now live at its new dedicated ADC site, which opened on a separate campus in late 2024. That factory already has customer booking capacity, with LigaChem Biosciences extending its ADC collaboration with Samsung Bio just last week. The new ADC site and Plant 5 are expected to help Samsung Bio grow in 2025, in spite of “industry challenges,” said CEO John Rim in the Tuesday release. Just yesterday, Charles River warned that last year’s headwinds will continue this year. Samsung Bio is also planning to invest in pre-filled syringe capabilities and expects to have an automated manufacturing line for drugs using this tech by 2027. The company will further invest in new technologies, including artificial intelligence, to speed up production timelines.

- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs INCHEON, South Korea, Jan. 14, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16. During the main track presentation, Samsung Biologics' CEO and President John Rim said, "Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the opening of Bio Campus II and launch of antibody-drug conjugate (ADC) services." He added, "We'll continue to invest in new modalities and technologies to better address client needs, maximizing satisfaction and ensuring the delivery of highest-quality products." Key business updates include: ADC services: To address the increasing demand for ADC-based therapeutics, Samsung Biologics has commenced ADC services at its new dedicated facility. Building on the company's expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics' service scope spans late stage discovery, development, and conjugation. Samsung Biologics recently expanded its collaboration with LigaChem Biosciences to support a series of their ADC programs at Samsung Biologics' new dedicated ADC facility. Opening of Japan office: To better support Samsung Biologics' expanding global client base, the company announced plans to open a regional office in Tokyo this year. The local presence will boost Samsung Biologics ability to support and grow its increasing partnerships in Japan. Expanded Drug Product (DP) services: As part of continued efforts to expand service offerings, Samsung Biologics is investing in pre-filled syringe (PFS) capabilities. The company's fully automated PFS DP line will be CGMP ready by 2027. Enhanced development capabilities: Samsung Biologics plans to better support global pharma and emerging biotech companies by investing in core development capabilities. The company is offering services incorporating new tech platforms, including S-HiConTM, S-TensifyTM, S-AfuCHOTM, and S-OptiChargeTM, that ensure higher productivity and quality of a molecule for successful and accelerated drug development. Capacity expansion: Samsung Biologics will mark a new phase of growth with the opening of Bio Campus II this year. Plant 5, the first facility of the new site, will be operational in April this year and bring up the total capacity to 784,000 liters. The company is also considering the construction of a sixth plant to proactively respond to the rising demand for biologics, which will increase total production capacity to 964,000 liters upon board approval. Digital transformation: As part of efforts to maximize operational efficiency and client satisfaction, Samsung Biologics will continue to invest in further building its integrated digital systems spanning quality, manufacturing, and operations. Incorporating artificial intelligence and digital twin technology, the company plans to provide clients with data-enabled solutions and insight to optimize project timelines without compromising quality. About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. Maximizing operational efficiency and expanding our capabilities in response to growing biomanufacturing demand, Samsung Biologics offers a combined 604 kL total capacity at Bio Campus I. The company launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025, adding 180 kL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in an ADC facility, mRNA technologies, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. Samsung Biologics Contact Claire Kim, Head of Global Marketing Communications [email protected] SOURCE Samsung Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED